Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephrology

Journal of Nephrology

Volumn 19, Issue 4, 2006, Pages 465-472

  Rasche, Franz Maximilian ^a   Keller, Frieder ^a   von Müller, Lutz ^a   Sailer, Leif Konradin ^a   Karges, Wolfram ^a   Czock, David ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cyclophosphamide; IgA nephropathy; Immunosuppression; Mycophenolic acid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENZALAPRIL; CANDESARTAN; CAPTOPRIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMMUNOSUPPRESSIVE AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION TEST; LINEAR REGRESSION ANALYSIS; MALE; PROSPECTIVE STUDY; PROTEINURIA; SINGLE BLIND PROCEDURE; BLOOD PRESSURE; DRUG EFFECT; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADULT; AGED; BLOOD PRESSURE; CYCLOPHOSPHAMIDE; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PROTEINURIA;

EID: 34249058826     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-48.
2. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24: 179-96.
3. Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59: 1077-85.
4. Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou. M, Novak J, Vrtovsnik E Haddad E, Chintalachariiiw-KRi Monteiro RC. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004; 15: 622-34.
5. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-97.
6. Harper L, Ferreira MA, Howie AJ, Savage CO, Richards NT, Michael J, Adu D. Treatment of vasculitic IgA nephropathy. J Nephrol 2000; 13: 360-6.
7. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18: 1321-9.
8. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant 2003; 18: 241-5.
9. Feehally J. Treating IgA nephropathy - who, when and how? Nephron Clin Pract 2003; 93: C47-8.
10. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-8.
11. Rasche FM, Klotz CH, Czock D, Karges W, Muche R, Jehle PM, Mertz A, Keller F. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract 2003; 93: 131-6.
12. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-7.
13. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-63.
14. Rasche FM, Sailer LC, Czock D, Keller F. Tonsillectomy, high dose immunoglobulins, and cyclophosphamide in progressive IgA-nephropathy. Acta Otolaryngol Suppl 2004: 32-7.
15. Izeradjene K, Revillard JP. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation 2001; 71: 118-25.
16. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80.
17. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-83.
18. Pesavento TE, Bay WH, Agarwal G, Hernandez RA Jr, Hebert LA. Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy. Am J Kidney Dis 2004; 43: e3-6.
19. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-12.
20. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-9.
21. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agad V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G. Mycophenolate mofetil. (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-45.
22. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-42.
23. Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, Katz AI. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol 1982; 13: 314-22.
24. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005; 16: 459-66.
25. Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M, Piccoli G, Sena LM. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000; 15: 833-5.
26. Locatelli F, Pozzi C, Del Vecchio L, Bolasco PG, Fogazzi GB, Andrulli S, Melis P, Altieri P, Ponticelli C. Role of proteinuria reduction in the progression of IgA nephropathy. Ren Fail 2001; 23: 495-505.
27. D'Amico G, Ragni A, Gandini E, Fellin G. Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 1993; 104: 6-13.
28. Scholl U, Wastl U, Risler T, Braun N, Grabensee B, Heering P, Schollmeyer P, Zauner I, Stein G, Funfstuck R, Keller F. The "point of no return" and the rate of progression in the natural history of IgA nephritis. Clin Nephrol 1999; 52: 285-92.
29. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nepbropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-83.
30. Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol 2005; 18: 354-61.
31. Karim MY, Abbs IC. Mycophenolate mofetil in nonlupus glomerulonephropathy. Lupus 2005; 14 (Suppl 1): s39-41.
32. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic: drugs. N Engl J Med 1986; 314: 614-9.
33. Czock D, Keller E, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44: 61-98.
34. Jonsson CA, Carlsten H. Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 2003; 3: 31-7.
35. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
36. Colic M, Stojic-Vukanic Z, Pavlovic Bjandric D, Stelanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003; 134: 63-9.
37. Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L. [A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy] [article in Chinese]. Zhonghua Yi Xue Za Zhi 2002; 82: 796-801.
38. Dal Canton A, Amore A, Barbano G, Coppo R, Emma F, Grandaliano G, Klersy C, Perfumo F, Rizzoni G, Schena FP, Sepe V; Angiotensin Inhibition Mycophenolate Mophetil IgA Nephropathy Study Investigators. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. J Nephrol 2005; 18:136-40.
39. Hogg RJ, Wyatt RJ; Scientific Planning Committee of the North American IgA Nephropathy Study. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62557616). BMC Nephrol 2004; 5: 3.
40. Neumann I, Haidinger M, Jager H, Grutzmacher H, Griesmacher A, Muller MM, Bayer PM, Meisl FT. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003; 14: 721-7.
41. Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ, Hilbrands LB, Vas P, van Gelder T, Hoitsma AJ, Weimar W. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68: 1603-6.
42. Glander P, Hambach P, Braun KP, Fritsche L, Waiser J, Mai I, Neumayer HH, Budde K Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003; 41: 470-6.